TNF Pharmaceuticals (TNFA) said Wednesday that Prevail Partners has agreed to acquire 283,019 common shares of the company at $2.12 apiece.
TNF said it has engaged Prevail Partners affiliate Prevail InfoWorks to offer clinical services for the next phase 2 clinical study using TNF's sarcopenia drug candidate.
The company said it is now fully funded for clinical trials for the next two years.
TNF shares were up 3.9% in recent trading.
Price: 1.51, Change: +0.06, Percent Change: +3.93
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。